Scientists have created a new type of experimental drug that works differently than current treatments for type 2 diabetes and obesity. Instead of just blocking an enzyme called 11β-HSD1, these new drugs actually remove the protein entirely from cells. In tests with mice fed a high-fat diet, the most effective drug candidate improved how their bodies handled blood sugar and boosted insulin production. This research represents an exciting new direction for treating metabolic diseases, though the drugs are still in early development stages and haven’t been tested in humans yet.
The Quick Take
- What they studied: Whether a completely new type of drug design could help treat type 2 diabetes by removing a specific protein that controls stress hormone levels in the body
- Who participated: Laboratory cell cultures and mice with diet-induced type 2 diabetes; no human participants in this early-stage research
- Key finding: The experimental drug called H-3-V successfully removed the target protein from cells and improved blood sugar control and insulin response in diabetic mice
- What it means for you: This is very early research showing a promising new approach, but it’s not ready for human use yet. It may eventually lead to new diabetes treatments, but several more years of testing are needed before we know if it’s safe and effective in people
The Research Details
This was a laboratory-based research study where scientists designed and tested new experimental drugs. They created several drug candidates using a new technology called PROTACs, which are molecules designed to remove unwanted proteins from cells rather than just blocking them. The researchers synthesized these drugs in the lab, tested them in cell cultures to see how well they worked, and then tested the most promising candidate in mice with type 2 diabetes caused by eating a high-fat diet. They also used computer simulations to understand how the best drug candidate attached to and interacted with its targets.
The study involved multiple phases: first creating the drug molecules, then testing them in isolated cells to measure how efficiently they removed the target protein, then testing the best performer in living mice to see if it improved their blood sugar control and insulin production. The researchers measured several outcomes including glucose tolerance (how well the body handles sugar) and insulin secretion (how much insulin the pancreas released in response to sugar).
This type of research is fundamental discovery work, meaning it’s exploring whether a new idea could work before any human testing would occur. The researchers used established scientific methods to validate their approach at each stage.
Traditional diabetes drugs work by blocking the activity of enzymes or proteins, like turning down a dimmer switch. This new PROTAC technology actually removes the protein entirely, like turning off the light switch completely. This could potentially be more effective because the protein can’t regain activity. Understanding whether this approach works for the 11β-HSD1 protein is important because this protein is involved in stress hormone regulation, which affects blood sugar control, weight, and inflammation—all key problems in type 2 diabetes and obesity.
This is early-stage research published in a peer-reviewed chemistry journal, which means other scientists reviewed the work before publication. The study includes multiple lines of evidence: cell-based experiments, animal testing, and computer modeling. However, this is not yet human research, so the results cannot be directly applied to people. The study doesn’t specify how many mice were tested, which is important information for evaluating the reliability of the animal results. The fact that this is published research suggests the methods were sound, but the findings need confirmation through further development and testing.
What the Results Show
The researchers successfully created several experimental drugs using the PROTAC technology, with one candidate called H-3-V showing the strongest effects. In cell cultures, H-3-V efficiently removed the 11β-HSD1 protein through the cell’s natural protein disposal system (the ubiquitin-proteasome pathway). This removal was dose-dependent, meaning higher concentrations of the drug led to more protein removal.
In mice with type 2 diabetes caused by a high-fat diet, treatment with H-3-V improved glucose tolerance—meaning the mice’s bodies handled blood sugar better after eating. The drug also increased glucose-stimulated insulin secretion, which means the pancreas released more insulin in response to rising blood sugar levels. These are both important markers of improved metabolic health and suggest the drug could help address core problems in type 2 diabetes.
Computer simulations showed that H-3-V formed stronger connections with its target proteins compared to less effective drug candidates, which helps explain why it worked better. The researchers identified specific molecular features that made H-3-V superior, providing insight into how to design even better versions in the future.
The study demonstrated that the PROTAC approach successfully recruits the cell’s natural protein-removal machinery to target 11β-HSD1. Different drug candidates showed varying levels of effectiveness, with the polyethylene glycol linker (the connecting piece between the functional parts of the drug) playing an important role in how well the drug worked. The research also showed that the approach was specific—the drugs targeted the intended protein without apparent off-target effects in the cell cultures tested.
Previous attempts to treat metabolic diseases by targeting 11β-HSD1 used inhibitor drugs that block the protein’s activity but leave the protein in place. This new PROTAC approach represents a fundamentally different strategy—removing the protein entirely rather than just disabling it. The improved glucose tolerance and insulin secretion seen in this study suggest this new approach may be more effective than previous inhibitor-based strategies, though direct comparisons in the same experiments weren’t performed. The PROTAC technology itself is relatively new and has shown promise for other disease targets, making this application to metabolic disease a logical extension of the field.
This study has several important limitations. First, it only tested the drugs in mice, not humans, so we don’t know if the results will translate to people. Second, the study doesn’t specify how many mice were used or provide detailed statistical analysis of the results, which makes it harder to assess how reliable the findings are. Third, only short-term effects were measured; we don’t know if the benefits would persist with long-term treatment or if side effects might develop. Fourth, the study focused on one aspect of metabolic disease (glucose control) and didn’t examine potential effects on weight loss, inflammation, or other metabolic markers. Finally, the drug is still in very early development, and many experimental drugs that work in mice fail to work in humans or cause unexpected side effects.
The Bottom Line
At this stage, there are no recommendations for human use because this research is preliminary. The findings suggest that PROTAC-based drugs targeting 11β-HSD1 warrant further development and testing. For people with type 2 diabetes, current approved treatments remain the evidence-based standard of care. Confidence level: This is very early-stage research (laboratory and animal studies only), so confidence in eventual human benefit is moderate at best. The approach is scientifically sound, but many steps remain before clinical application.
This research is most relevant to: (1) researchers and pharmaceutical companies developing new diabetes treatments, (2) people with type 2 diabetes or obesity who might eventually benefit from new treatment options, and (3) scientists interested in PROTAC technology and protein degradation approaches. This research should NOT influence current treatment decisions for anyone with diabetes—existing medications remain the appropriate choice. People with metabolic disorders should continue following their doctor’s current treatment recommendations.
This is very early-stage research. Realistic timeline expectations: 3-5 years for additional laboratory and animal testing, 5-10 years for initial human safety testing (if the drug advances), and potentially 10-15 years before a drug could be available to patients (if all testing goes well). Many experimental drugs never make it through development, so there’s no guarantee this specific drug will ever reach patients.
Want to Apply This Research?
- While this drug is not yet available, users interested in metabolic health could track: fasting blood glucose levels (if they have diabetes), weight, energy levels, and hunger patterns. This creates a baseline for comparing against future treatments if they become available.
- Users could use the app to monitor and improve lifestyle factors that complement any future metabolic treatments: tracking daily steps/activity, logging meals to monitor carbohydrate intake, recording sleep quality, and monitoring stress levels. These behaviors support metabolic health regardless of medications.
- Set up long-term tracking of metabolic markers (blood sugar, weight, energy) and lifestyle factors. When new treatments become available, this historical data provides a comparison point to assess whether new medications provide additional benefits beyond current lifestyle management.
This research describes early-stage experimental drugs that have only been tested in laboratory cells and mice. These drugs are not approved for human use and are not available as treatments. This article is for educational purposes only and should not influence medical decisions. People with type 2 diabetes, obesity, or other metabolic conditions should continue following their healthcare provider’s current treatment recommendations. Do not delay, avoid, or discontinue any current diabetes medications based on this research. Always consult with your doctor before making any changes to your diabetes management plan. Future human testing may show that these experimental drugs are ineffective or cause side effects not seen in animal studies.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.